MDIG promotes cisplatin resistance of lung adenocarcinoma by regulating ABC transporter expression via activation of the WNT/β‑catenin signaling pathway

Wang,Qing; Geng,Feng; Zhou,Haomin; Chen,Yecheng; Du,Juan; Zhang,Xinyu; Song,Dandan; Zhao,Hongwen

doi:10.3892/ol.2019.10774

MDIG promotes cisplatin resistance of lung adenocarcinoma by regulating ABC transporter expression via activation of the WNT/β‑catenin signaling pathway

Authors:
- Qing Wang
- Feng Geng
- Haomin Zhou
- Yecheng Chen
- Juan Du
- Xinyu Zhang
- Dandan Song
- Hongwen Zhao
View Affiliations

Affiliations: Department of Pulmonary Medicine, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: August 22, 2019 https://doi.org/10.3892/ol.2019.10774
Pages: 4294-4307

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mineral dust‑induced gene (MDIG) is a proto‑oncogene associated with lung cancer that serves a key role in the biological processes of tumorigenesis. The aim of the present study was to determine whether MDIG is involved in cisplatin (DDP) resistance in lung adenocarcinoma, and to investigate the associated molecular mechanism. In the present study, MDIG‑knockdown and MDIG‑overexpressing A549 cells and DDP‑resistant A549/DDP cells were initially constructed, and then the mRNA and protein expression levels of MDIG and ATP‑binding cassette (ABC) transporters (ABCB1, ABCC1, ABCG2), and the expression levels of the major associated proteins in the WNT/β‑catenin pathway were determined by reverse transcription‑quantitative PCR and Western blotting experiments. The results revealed that the mRNA and protein expression levels of MDIG in A549/DDP cells were significantly higher compared with those in A549 cells, and that the protein expression levels of MDIG increased in a dose‑dependent manner with increasing DDP concentrations. Overexpression of MDIG in A549 and A549/DDP cells led to an increase in the IC50 value, whereas silencing of MDIG led to a clear reduction in the IC50 value. The overexpression of MDIG in the A549 and A549/DDP cells markedly upregulated the mRNA and protein expression levels of ABCB1, ABCC1, ABCG2, WNT family member 5A, WNT family member 3A and active β‑catenin, and these were markedly decreased following MDIG silencing. Taken together, these results demonstrated that the DDP resistance of lung adenocarcinoma may be associated with an upregulation of MDIG expression, and that the expression levels of MDIG are positively associated with the degree of DDP resistance. Furthermore, MDIG promoted the expression of ABC transporters in tumor cells by activating the WNT/β‑catenin signaling pathway, which may, in turn, lead to DDP resistance in lung adenocarcinoma.

View Figures

View References

1	de Groot P and Munden RF: Lung cancer epidemiology, risk factors, and prevention. Radiol Clin North Am. 50:863–876. 2012. View Article : Google Scholar : PubMed/NCBI
2	Ma D, Guo D, Li W and Zhao H: MDIG, a lung cancer-associated gene, regulates cell cycle progression through p27(KIP1). Tumour Biol. 36:6909–6917. 2015. View Article : Google Scholar : PubMed/NCBI
3	Lu HY, Wang XJ and Mao WM: Targeted therapies in small cell lung cancer. Oncol Lett. 5:3–11. 2013.PubMed/NCBI
4	Guo Y, Chu M, Tan S, Zhao S, Liu H, Otieno BO, Yang X, Xu C and Zhang Z: Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance. Mol Pharm. 11:59–70. 2014. View Article : Google Scholar : PubMed/NCBI
5	Wu Q, Yang Z, Nie Y, Shi Y and Fan D: Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Lett. 347:159–166. 2014. View Article : Google Scholar : PubMed/NCBI
6	Calatozzolo C, Gelati M, Ciusani E, Sciacca FL, Pollo B, Cajola L, Marras C, Silvani A, Vitellaro-Zuccarello L, Croci D, et al: Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol. 74:113–121. 2005. View Article : Google Scholar : PubMed/NCBI
7	Cui H, Zhang AJ, Chen M and Liu JJ: ABC transporter inhibitors in reversing multidrug resistance to chemotherapy. Curr Drug Targets. 16:1356–1371. 2015. View Article : Google Scholar : PubMed/NCBI
8	Mohammad IS, He W and Yin L: Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR. Biomed Pharmacother. 100:335–348. 2018. View Article : Google Scholar : PubMed/NCBI
9	Hung TH, Hsu SC, Cheng CY, Choo KB, Tseng CP, Chen TC, Lan YW, Huang TT, Lai HC, Chen CM and Chong KY: WNT5A regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/β-catenin pathway. Oncotarget. 5:12273–12290. 2014. View Article : Google Scholar : PubMed/NCBI
10	Chen B, Zhang D, Kuai J, Cheng M, Fang X and Li G: Upregulation of miR-199a/b contributes to cisplatin resistance via WNT/β-catenin-ABCG2 signaling pathway in ALDHA1⁺ colorectal cancer stem cells. Tumour Biol. 39:10104283177151552017. View Article : Google Scholar : PubMed/NCBI
11	Zhang Y, Lu Y, Yuan BZ, Castranova V, Shi X, Stauffer JL, Demers LM and Chen F: The Human mineral dust-induced gene, MDIG, is a cell growth regulating gene associated with lung cancer. Oncogene. 24:4873–4882. 2005. View Article : Google Scholar : PubMed/NCBI
12	Tsuneoka M, Koda Y, Soejima M, Teye K and Kimura H: A novel myc target gene, mina53, that is involved in cell proliferation. J Biol Chem. 277:35450–35459. 2002. View Article : Google Scholar : PubMed/NCBI
13	Eilbracht J, Kneissel S, Hofmann A and Schmidt-Zachmann MS: Protein NO52-a constitutive nucleolar component sharing high sequence homologies to protein NO66. Eur J Cell Biol. 84:279–294. 2005. View Article : Google Scholar : PubMed/NCBI
14	Yu M, Sun J, Thakur C, Chen B, Lu Y, Zhao H and Chen F: Paradoxical roles of mineral dust induced gene on cell proliferation and migration/invasion. PLoS One. 9:e879982014. View Article : Google Scholar : PubMed/NCBI
15	Thakur C, Wolfarth M, Sun J, Zhang Y, Lu Y, Battelli L, Porter DW and Chen F: Oncoprotein MDIG contributes to silica-induced pulmonary fibrosis by altering balance between Th17 and Treg T cells. Oncotarget. 6:3722–3736. 2015. View Article : Google Scholar : PubMed/NCBI
16	Chen B, Yu M, Chang Q, Lu Y, Thakur C, Ma D, Yi Z and Chen F: MDIG de-represses H19 large intergenic non-coding RNA (lincRNA) by down-regulating H3K9me3 and heterochromatin. Oncotarget. 4:1427–1437. 2013. View Article : Google Scholar : PubMed/NCBI
17	Wu K, Tan MY, Jiang JT, Mu XY, Wang JR, Zhou WJ, Wang X, Li MQ, He YY and Liu ZH: Cisplatin inhibits the progression of bladder cancer by selectively depleting G-MDSCs: A novel chemoimmunomodulating strategy. Clin Immunol. 193:60–69. 2018. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Luo K, Gu X, Liu J, Zeng G, Peng L, Huang H, Jiang M, Yang P, Li M, Yang Y, et al: Inhibition of disheveled-2 resensitizes cisplatin-resistant lung cancer cells through down-regulating WNT/β-catenin signaling. Exp Cell Res. 347:105–113. 2016. View Article : Google Scholar : PubMed/NCBI
20	Corrêa S, Binato R, Du Rocher B, Castelo-Branco MT, Pizzatti L and Abdelhay E: WNT/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer. 12:3032012. View Article : Google Scholar : PubMed/NCBI
21	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
22	Zhou C: Lung cancer molecular epidemiology in China: Recent trends. Transl Lung Cancer Res. 3:270–279. 2014.PubMed/NCBI
23	Reck M, Heigener DF, Mok T, Soria JC and Rabe KF: Management of non-small-cell lung cancer: Recent developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
24	Thakur C, Lu Y, Sun J, Yu M, Chen B and Chen F: Increased expression of MDIG predicts poorer survival of the breast cancer patients. Gene. 535:218–224. 2014. View Article : Google Scholar : PubMed/NCBI
25	Teye K, Tsuneoka M, Arima N, Koda Y, Nakamura Y, Ueta Y, Shirouzu K and Kimura H: Increased expression of a Myc target gene Mina53 in human colon cancer. Am J Pathol. 164:205–216. 2004. View Article : Google Scholar : PubMed/NCBI
26	Ogasawara S, Komuta M, Nakashima O, Akiba J, Tsuneoka M and Yano H: Accelerated expression of a Myc target gene Mina53 in aggressive hepatocellular carcinoma. Hepatol Res. 40:330–336. 2010. View Article : Google Scholar : PubMed/NCBI
27	Ishizaki H, Yano H, Tsuneoka M, Ogasawara S, Akiba J, Nishida N, Kojiro S, Fukahori S, Moriya F, Matsuoka K and Kojiro M: Overexpression of the myc target gene Mina53 in advanced renal cell carcinoma. Pathol Int. 57:672–680. 2007. View Article : Google Scholar : PubMed/NCBI
28	Fukahori S, Yano H, Tsuneoka M, Tanaka Y, Yagi M, Kuwano M, Tajiri T, Taguchi T, Tsuneyoshi M and Kojiro M: Immunohistochemical expressions of Cap43 and Mina53 proteins in neuroblastoma. J Pediatr Surg. 42:1831–1840. 2007. View Article : Google Scholar : PubMed/NCBI
29	Huo Q, Ge C, Tian H, Sun J, Cui M, Li H, Zhao F, Chen T, Xie H, Cui Y, et al: Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity. Cell Death Dis. 8:e27662017. View Article : Google Scholar : PubMed/NCBI
30	Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T and Bates SE: Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol. 75:1302–1312. 2008. View Article : Google Scholar : PubMed/NCBI
31	Shi Z, Parmar S, Peng XX, Shen T, Robey RW, Bates SE, Fu LW, Shao Y, Chen YM, Zang F and Chen ZS: The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncol Rep. 21:483–489. 2009.PubMed/NCBI
32	Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, Nishiwaki Y, Kodama T, Suga M and Ochiai A: Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res. 10:1691–1697. 2004. View Article : Google Scholar : PubMed/NCBI
33	Li A, Song J, Lai Q, Liu B, Wang H, Xu Y, Feng X, Sun X and Du Z: Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line. Int J Exp Pathol. 97:412–421. 2016. View Article : Google Scholar : PubMed/NCBI
34	Pei K, Zhu JJ, Wang CE, Xie QL and Guo JY: MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1. Eur Rev Med Pharmacol Sci. 20:4697–4704. 2016.PubMed/NCBI
35	Huang L, Jin Y, Feng S, Zou Y, Xu S, Qiu S, Li L and Zheng J: Role of WNT/β-catenin, WNT/c-Jun N-terminal kinase and WNT/Ca²⁺ pathways in cisplatin-induced chemoresistance in ovarian cancer. Exp Ther Med. 12:3851–3858. 2016. View Article : Google Scholar : PubMed/NCBI
36	Li Z, Zhao L and Wang Q: Overexpression of long non-coding RNA HOTTIP increases chemoresistance of osteosarcoma cell by activating the WNT/β-catenin pathway. Am J Transl Res. 8:2385–2393. 2016.PubMed/NCBI